Novartis slightly raises 2025 earnings forecast, citing strong Q2

Novartis has slightly raised its full-year core operating income growth forecast to 'low teens' from 'low double-digits,' following a robust second quarter. Second-quarter adjusted operating income rose 20% to $5.93 billion, propelled by significant sales increases for key drugs like breast cancer treatment Kisqali (up 64% to $1.2 billion) and multiple sclerosis drug Kesimpta (up 35% to $1.1 billion). This strong financial performance and confidence in future growth have led the company to initiate an up-to $10 billion share buyback program, signaling a commitment to shareholder returns.

Analysis

Novartis has issued a positive revision to its full-year 2025 earnings forecast, upgrading its expected core operating income growth from "low double-digits" to "low teens." This enhanced outlook is directly supported by a robust second-quarter performance, where adjusted operating income climbed 20% to $5.93 billion. The growth is fueled by exceptional performance in key drug franchises, specifically the breast cancer treatment Kisqali, which saw a 64% revenue jump to $1.2 billion, and the multiple sclerosis drug Kesimpta, with a 35% sales surge to $1.1 billion. Underscoring management's confidence in sustained momentum and financial health, the company has also initiated a significant capital return program with an up-to $10 billion share buyback, which CEO Vas Narasimhan attributed to a robust balance sheet and a positive mid-to-long-term growth outlook.

Key Decisions for Investors

• The combination of an upgraded earnings forecast and strong underlying sales growth for key products like Kisqali and Kesimpta strengthens the bullish case for the stock.
• Investors should view the new $10 billion share buyback program as a significant catalyst for shareholder value, reflecting management's confidence and providing a potential floor for the stock price.
• Future performance is heavily dependent on the continued trajectory of its high-growth drugs; therefore, monitoring the quarterly sales figures for Kisqali and Kesimpta is critical to validating the investment thesis.